BRCA1/2突变携带者乳腺局部治疗与同侧乳腺癌复发率
单中心回顾性分析2006–2020年255例BRCA1/2突变乳腺癌患者,比较乳房切除±放疗与保乳治疗的同侧乳腺肿瘤复发(IBTR)。未放疗的乳房切除组IBTR累积率11.8%,高于放疗组0/52和保乳组4.7%;5年及10年IBTR在未放疗组为9.8%和27.4%,保乳组为2%和11.3%。
要点
- BRCA1/2携带者乳房切除未放疗组IBTR高于放疗组和保乳组。
- 未放疗组5年IBTR 9.8%、10年27.4%,保乳组为2%和11.3%。
- 随访期总生存无显著差异,SSM/NSM安全性需前瞻性试验评估。
核心结论
- BRCA1/2突变携带者接受乳房切除未行术后放疗者IBTR高于乳房切除加放疗或保乳治疗者,尽管前者分期更早。
研究设计与样本
- 单中心回顾性研究,纳入2006–2020年诊断并治疗的255例BRCA1/2胚系突变乳腺癌患者。
主要发现
- 255例中128例(50.2%)行乳房切除,其中82%为SSM或NSM;76例(59.4%)未行术后放疗,52例(40.6%)行术后放疗;127例(49.8%)选择保乳治疗。
- 未放疗组IBTR为9/76(11.8%),放疗组为0/52(P=.01),保乳组为6/127(4.7%)(P=.06)。
- 未放疗组5年和10年IBTR累积发生率分别为9.8%和27.4%,保乳组分别为2%和11.3%(P=.0183)。
- 随访时总生存无显著差异。
关键数值与推荐
- 未放疗组早期疾病比例更高:82.3%为Tis和T1N0,放疗组和保乳组分别为3.6%和48.1%(P<.05)。
临床怎么用
- BRCA1/2携带者选择乳房切除(尤其SSM/NSM)而未行术后放疗时,需关注较高的IBTR风险。
- 保乳治疗在BRCA1/2携带者中显示出较低的IBTR累积率,可作为局部治疗选项之一。
局限性
- 回顾性单中心设计,样本量有限,SSM/NSM安全性需前瞻性试验评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There is a paucity of data on the rates of ipsilateral breast tumor recurrence (IBTR) in BRCA1/2-associated breast cancer (BC). Scarcer yet are outcomes data in BRCA1/2 mutation carriers in the setting of newer mastectomy techniques, such as skin-sparing mastectomies (SSM) and nipple-sparing mastectomies (NSM). METHODS: Data were extracted from the medical records of BRCA1/2 carriers who were diagnosed with BC and treated at a single institution between 2006 and 2020. The data extracted included patient demographics, tumor characteristics, disease stage, surgical treatment, use of radiation therapy (RT), and disease outcome. RESULTS: Overall, 255 BC patients with BRCA1/2 germline mutations were identified. Of these, 128 (50.2%) underwent a mastectomy (SSM or NSM in 82% of them), 76 (59.4%) without postmastectomy RT (non-PMRT) and 52 (40.6%) with PMRT, whereas 127 (49.8%) elected for breast-conserving treatment (BCT). The non-PMRT group had earlier disease stages (82.3% were Tis and T1N0) compared with the PMRT and BCT groups (3.6% and 48.1%, respectively; P < .05). The IBTR cumulative rate was 9 of 76 (11.8%) in the non-PMRT cohort compared with 0 of 52 in the PMRT group (P = .01) and 6 of 127 (4.7%) in the BCT group (P = .06). The cumulative incidences of IBTR at 5 and 10 years were 9.8% and 27.4%, respectively, in the non-PMRT group versus 2% and 11.3%, respectively, in the BCT group (P = .0183). No significant difference in overall survival was observed at the time of follow-up. CONCLUSIONS: BRCA1/2 mutation carriers treated with mastectomy without PMRT had higher rates of IBTR than those who underwent mastectomy and PMRT or BCT, despite earlier stages of disease. The safety of SSM/NSM should be evaluated in a prospective trial.
引用
- Bernstein-Molho R, Laitman Y, Galper S, et al. Locoregional Treatments and Ipsilateral Breast Cancer Recurrence Rates in BRCA1/2 Mutation Carriers. Int J Radiat Oncol Biol Phys. 2020. PMID: 33259931. doi:10.1016/j.ijrobp.2020.11.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。